Abstract
Gastric cancer is an active topic of clinical and basic research due to high morbidity and mortality. To date, gastrectomy and chemotherapy are the only therapeutic options for gastric cancer patients, but drug resistance, either acquired or primary, is the main cause for treatment failure. Differences in development and response to cancer treatments have been observed among ethnically diverse GC patient populations. In spite of major incidence, GC Asian patients have a significantly better prognosis and response to treatments than Caucasian ones due to genetic discordances between the two populations. Gene therapy could be an alternative strategy to overcome such issues and especially CRISPR/Cas9 represents one of the most intriguing gene-editing system. Thus, in this review article, we want to provide an update on the currently used therapies for the treatment of advanced GC.
Similar content being viewed by others
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492.
Ishaq, S., & Nunn, L. (2015). Helicobacter pylori and gastric cancer: a state of the art review. Gastroenterology and Hepatology from Bed to Bench, 8(Suppl 1), S6–S14.
Kim, J., Cho, Y. A., Choi, W. J., & Jeong, S. H. (2014). Gene-diet interactions in gastric cancer risk: A systematic review. World Journal of Gastroenterology, 20(28), 9600–9610. https://doi.org/10.3748/wjg.v20.i28.9600.
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Continuous update project report: diet, nutrition, physical activity and stomach cancer 2016. Revised 2018. London: World Cancer Research Fund International; 2018.
Casamayor, M., Morlock, R., Maeda, H., & Ajani, J. (2018). Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience., 12, 883. https://doi.org/10.3332/ecancer.2018.883 eCollection 2018.
Berlth, F., Bollschweiler, E., Drebber, U., Hoelscher, A. H., & Moenig, S. (2014). Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World Journal of Gastroenterology, 20(19), 5679–5684. https://doi.org/10.3748/wjg.v20.i19.5679.
Clements, W. M., Wang, J., Sarnaik, A., Kim, O. J., MacDonald, J., Fenoglio-Preiser, C., Groden, J., & Lowy, A. M. (2002). Beta-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Research, 62(12), 3503–3506.
Feng, R., Chen, X., Yu, Y., Su, L., Yu, B., Li, J., Cai, Q., Yan, M., Liu, B., & Zhu, Z. (2010). miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Letters, 298, 50–63.
Moses, C., Garcia-Bloj, B., Harvey, A. R., & Blancafort, P. (2018). Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 93, 10–18. https://doi.org/10.1016/j.ejca.2018.01.002.
Su, S., Zou, Z., Chen, F., Ding, N., Du, J., Shao, J., Li, L., Fu, Y., Hu, B., Yang, Y., Sha, H., Meng, F., Wei, J., Huang, X., & Liu, B. (2016). CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology, 6(1), e1249558. https://doi.org/10.1080/2162402X.2016.1249558.
Deng, X., & Nakamura, Y. (2017). Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends in Pharmacological Sciences, 38(1), 15–24. https://doi.org/10.1016/j.tips.2016.10.013.
Gao, Q., Dong, X., Xu, Q., Zhu, L., Wang, F., Hou, Y., & Chao, C. C. (2019). Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. Cancer Medicine. https://doi.org/10.1002/cam4.2257.
Dolcetti, R., De Re, V., Canzonieri, V. (2018). Immunotherapy for gastric cancer: time for a personalized approach? International Journal of Molecular Sciences, 19(6). doi:https://doi.org/10.3390/ijms19061602.
Cong, L., Zhou, R., Kuo, Y. C., Cunniff, M., & Zhang, F. (2012). Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nature Communications, 3, 968. https://doi.org/10.1038/ncomms1962.
Garcia-Bloj, B., Moses, C., Sgro, A., Plani-Lam, J., Arooj, M., Duffy, C., Thiruvengadam, S., Sorolla, A., Rashwan, R., Mancera, R. L., Leisewitz, A., Swift-Scanlan, T., Corvalan, A. H., & Blancafort, P. (2016). Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget, 7(37), 60535–60554. https://doi.org/10.18632/oncotarget.11142.
Liu, J., Ben, Q., Lu, E., He, X., Yang, X., Ma, J., Zhang, W., Wang, Z., Liu, T., Zhang, J., & Wang, H. (2018). Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer. Cell Death & Disease, 9(2), 168. https://doi.org/10.1038/s41419-017-0246-6.
Wagner, A. D., Unverzagt, S., Grothe, W., et al. (2010). Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews, 3, CD004064.
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., Kang, Y. K., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687–697.
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H., & Takeuchi, M. (2008). S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. The Lancet Oncology, 9, 215–221.
Ajani, J. A., Buyse, M., Lichinitser, M., et al. (2013). Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer study. Eur J Cancer, 49, 3616–3624.
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010). Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology, 28, 1547–1553.
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991–4997.
Al-Batran, S. E., Homann, N., & Pauligk, C. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 393(10184), 1948–1957.
Catalano, V., Graziano, F., Santini, D., D'Emidio, S., Baldelli, A. M., Rossi, D., Vincenzi, B., Giordani, P., Alessandroni, P., Testa, E., Tonini, G., & Catalano, G. (2008). Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? British Journal of Cancer, 99, 1402–1407.
Hang, Y., Ma, B., Huang, X. T., et al. (2016). Doublet versus single agent as second-line treatment for advanced gastric cancer: a meta-analysis of 10 randomized controlled trials. Medicine, 95, e2792.
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, J. R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A. M., Gao, L., Schwartz, J. D., & Tabernero, J. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 383, 31–39.
Wilke, H., Muro, K., Van Cutsem, E., et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology, 15, 1224–1235.
Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). Metastatic spread in patients with gastric cancer. Oncotarget, 7(32), 52307–52316. https://doi.org/10.18632/oncotarget.10740.
Thomassen, I., van Gestel, Y. R., van Ramshorst, B., Luyer, M. D., Bosscha, K., Nienhuijs, S. W., Lemmens, V. E., & de Hingh, I. H. (2014). Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. International Journal of Cancer, 134(3), 622–628. https://doi.org/10.1002/ijc.28373.
Kanda, M., & Kodera, Y. (2016). Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 22(30), 6829–6840. https://doi.org/10.3748/wjg.v22.i30.6829Review.
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K. M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., Ye, X. S., Do, I. G., Liu, S., Gong, L., Fu, J., Jin, J. G., Choi, M. G., Sohn, T. S., Lee, J. H., Bae, J. M., Kim, S. T., Park, S. H., Sohn, I., Jung, S. H., Tan, P., Chen, R., Hardwick, J., Kang, W. K., Ayers, M., Hongyue, D., Reinhard, C., Loboda, A., Kim, S., & Aggarwal, A. (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 21(5), 449–456. https://doi.org/10.1038/nm.3850.
Kim, B., Shin, H. C., Heo, Y. J., Ha, S. Y., Jang, K. T., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. M. (2019). CCNE1 amplification is associated with liver metastasis in gastric carcinoma. Pathology, Research and Practice, 4, 152434. https://doi.org/10.1016/j.prp.2019.152434.
Zhang, J., Huang, J. Y., Chen, Y. N., Yuan, F., Zhang, H., Yan, F. H., Wang, M. J., Wang, G., Su, M., Lu, G., Huang, Y., Dai, H., Ji, J., Zhang, J., Zhang, J. N., Jiang, Y. N., Chen, S. J., Zhu, Z. G., & Yu, Y. Y. (2015). Erratum: whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma. Scientific Reports, 5, 15309. https://doi.org/10.1038/srep15309.
Fang, W. L., Lan, Y. T., Huang, K. H., Liu, C. A., Hung, Y. P., Lin, C. H., Jhang, F. Y., Chang, S. C., Chen, M. H., Chao, Y., Lin, W. C., Lo, S. S., Fen-Yau Li, A., Wu, C. W., Chiou, S. H., & Shyr, Y. M. (2016). Clinical significance of circulating plasma DNA in gastric cancer. International Journal of Cancer, 138(12), 2974–2983. https://doi.org/10.1002/ijc.30018.
Wang, R., Song, S., Harada, K., Ghazanfari Amlashi, F., Badgwell, B., Pizzi, M. P., Xu, Y., Zhao, W., Dong, X., Jin, J., Wang, Y., Scott, A., Ma, L., Huo, L., Vicente, D., Blum Murphy, M., Shanbhag, N., Tatlonghari, G., Thomas, I., Rogers, J., Kobayashi, M., Vykoukal, J., Estrella, J. S., Roy-Chowdhuri, S., Han, G., Zhang, S., Mao, X., Song, X., Zhang, J., Gu, J., Johnson, R. L., Calin, G. A., Peng, G., Lee, J. S., Hanash, S. M., Futreal, A., Wang, Z., Wang, L., & Ajani, J. A. (2019). Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. https://doi.org/10.1136/gutjnl-2018-318070.
Wang, J., Sun, Y., & Bertagnolli, M. M. (2015). Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Annals of Surgical Oncology, 22(9), 2965–2971. https://doi.org/10.1245/s10434-015-4388-4.
Stock, M., & Otto, F. (2005). Gene deregulation in gastric cancer. Gene., 360(1), 1–19 Review.
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians, 55(2), 74–108.
Jia, F., Teer, J. K., Knepper, T. C., Lee, J. K., Zhou, H. H., He, Y. J., & McLeod, H. L. (2017). Discordance of somatic mutations between Asian and Caucasian patient populations with gastric cancer. Molecular Diagnosis & Therapy, 21(2), 179–185. https://doi.org/10.1007/s40291-016-0250-z.
Kim, J., Sun, C. L., Mailey, B., Prendergast, C., Artinyan, A., Bhatia, S., Pigazzi, A., & Ellenhorn, J. D. (2010). Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Annals of Oncology, 21(1), 152–160. https://doi.org/10.1093/annonc/mdp290.
Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., & Print, C. (2010). Predictive and prognostic molecular markers for cancer medicine. Therapeutic Advances in Medical Oncology, 2(2), 125–148. https://doi.org/10.1177/1758834009360519.
Pinheiro Ddo, R., Ferreira, W. A., Barros, M. B., Araújo, M. D., Rodrigues-Antunes, S., & Borges, B. N. (2014). Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications. World Journal of Gastroenterology, 20(33), 11574–11585. https://doi.org/10.3748/wjg.v20.i33.11574Review.
Abrahao-Machado, L. F., & Scapulatempo-Neto, C. (2016). HER2 testing in gastric cancer: an update. World Journal of Gastroenterology, 22(19), 4619–4625. https://doi.org/10.3748/wjg.v22.i19.4619Review.
Lordick, F., Lorenzen, S., Yamada, Y., & Ilson, D. (2014). Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer, 17(2), 213–225. https://doi.org/10.1007/s10120-013-0297-zReview.
Chou, S. T., Leng, Q., & Mixson, A. J. (2012). Zinc finger nucleases: tailor-made for gene therapy. Drugs of the Future, 37(3), 183–196.
Silva, G., Poirot, L., Galetto, R., Smith, J., Montoya, G., Duchateau, P., & Pâques, F. (2011). Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Current Gene Therapy, 11(1), 11–27 Review.
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., Dulay, G. P., Hua, K. L., Ankoudinova, I., Cost, G. J., Urnov, F. D., Zhang, H. S., Holmes, M. C., Zhang, L., Gregory, P. D., & Rebar, E. J. (2011). A TALE nuclease architecture for efficient genome editing. Nature Biotechnology, 29(2), 143–148. https://doi.org/10.1038/nbt.1755.
Lee, H. J., Kim, E., & Kim, J. S. (2010). Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Research, 20(1), 81–89. https://doi.org/10.1101/gr.099747.109.
Liang, F., Han, M., Romanienko, P. J., & Jasin, M. (1998). Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5172–5177.
Garneau, J. E., Dupuis, M. È., Villion, M., Romero, D. A., Barrangou, R., Boyaval, P., Fremaux, C., Horvath, P., Magadán, A. H., & Moineau, S. (2010). The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature., 468(7320), 67–71. https://doi.org/10.1038/nature09523.
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell., 156(5), 935–949. https://doi.org/10.1016/j.cell.2014.02.001.
Haft, D. H., Selengut, J., Mongodin, E. F., & Nelson, K. E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS Computational Biology, 1(6), e60.
Dow, L. E., Fisher, J., O'Rourke, K. P., Muley, A., Kastenhuber, E. R., Livshits, G., Tschaharganeh, D. F., Socci, N. D., & Lowe, S. W. (2015). Inducible in vivo genome editing with CRISPR-Cas9. Nature Biotechnology, 33(4), 390–394. https://doi.org/10.1038/nbt.3155.
Zhang, Y. Q., Pei, J. H., Shi, S. S., Guo, X. S., Cui, G. Y., Li, Y. F., Zhang, H. P., & Hu, W. Q. (2019). CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells. Biomedicine & Pharmacotherapy, 111, 76–85. https://doi.org/10.1016/j.biopha.2018.12.048.
Hilton, I. B., D’Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology, 33, 510–517.
Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., Ter-Ovanesyan, D., Braff, J. L., Davidsohn, N., et al. (2015). Highly efficient Cas9-mediated transcriptional programming. Nature Methods, 12, 326–328.
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., Guilak, F., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2013). RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nature Methods, 10, 973–976.
Sandoval-Bórquez, A., Saavedra, K., Carrasco-Avino, G., Garcia-Bloj, B., Fry, J., Wichmann, I., & Corvalán, A. H. (2015). Noncoding genomics in gastric cancer and the gastric precancerous cascade: pathogenesis and biomarkers. Disease Markers, 2015, 1–14.
Bernal, C., Aguayo, F., Villarroel, C., Vargas, M., Díaz, I., Ossandon, F. J., Santibáñez, E., Palma, M., Aravena, E., Barrientos, C., & Corvalan, A. H. (2008). Reprimo as a potential biomarker for early detection in gastric cancer. Clinical Cancer Research, 14, 6264–6269.
Kanda, T., Furuse, Y., Oshitani, H., & Kiyono, T. (2016). Highly efficient CRISPR/Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein-Barr virus strains. Journal of Virology, 90(9), 4383–4393. https://doi.org/10.1128/JVI.00060-16.Print2016May.
Corso, G., Marrelli, D., & Roviello, F. (2012). Familial gastric cancer and germline mutations of E-cadherin. Annali Italiani di Chirurgia, 83(3), 177–182.
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., Caldas, C., Schreiber, K. E., Hardwick, R. H., Ausems, M. G., Bardram, L., Benusiglio, P. R., Bisseling, T. M., Blair, V., Bleiker, E., Boussioutas, A., Cats, A., Coit, D., DeGregorio, L., Figueiredo, J., Ford, J. M., Heijkoop, E., Hermens, R., Humar, B., Kaurah, P., Keller, G., Lai, J., Ligtenberg, M. J., O'Donovan, M., Oliveira, C., Pinheiro, H., Ragunath, K., Rasenberg, E., Richardson, S., Roviello, F., Schackert, H., Seruca, R., Taylor, A., Ter Huurne, A., Tischkowitz, M., Joe, S. T., van Dijck, B., van Grieken, N. C., van Hillegersberg, R., van Sandick, J. W., Vehof, R., van Krieken, J. H., & Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of Medical Genetics, 52(6), 361–374. https://doi.org/10.1136/jmedgenet-2015-103094.
Biagioni, A., Laurenzana, A., Margheri, F., Chillà, A., Fibbi, G., & Del Rosso, M. (2018). Delivery systems of CRISPR/Cas9-based cancer gene therapy. Journal of Biological Engineering, 12, 33. https://doi.org/10.1186/s13036-018-0127-2eCollection 2018. Review.
Cepko, C., & Pear, W. (2001). Overview of the retrovirus transduction system. Current Protocols in Molecular Biology, 9, 9.9.
Annunziato, S., Kas, S. M., Nethe, M., Yücel, H., Del Bravo, J., Pritchard, C., Bin Ali, R., et al. (2016). Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes & Development, 30(12), 1470–1480.
English, D. P., Roque, D. M., & Santin, A. D. (2013). HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Molecular Diagnosis & Therapy, 17(2), 85–99. https://doi.org/10.1007/s40291-013-0024-9Review.
Koizumi, W., Tanabe, S., Saigenji, K., Ohtsu, A., Boku, N., Nagashima, F., Shirao, K., Matsumura, Y., & Gotoh, M. (2003). Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. British Journal of Cancer, 89(12), 2207–2212.
Ohtsu, Y., Shimada, K., Shirao, N., Boku, I., Hyodo, H., & Saito. (et al.). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). Journal of Clinical Oncology, 21(2003), 54e59.
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991e4997.
Narahara, H., Iishi, H., Imamura, H., Tsuburaya, A., Chin, K., Imamoto, H., Esaki, T., Furukawa, H., Hamada, C., & Sakata, Y. (2011). Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer, 14(1), 72–80. https://doi.org/10.1007/s10120-011-0009-5.
Das, K., Chan, X. B., Epstein, D., Teh, B. T., Kim, K. M., Kim, S. T., Park, S. H., Kang, W. K., Rozen, S., Lee, J., & Tan, P. (2016). NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open, 1, e000009.
Liu, S., Chapman, J. A., Burnell, M. J., Levine, M. N., Pritchard, K. I., Whelan, T. J., Rugo, H. S., Albain, K. S., Perez, E. A., Virk, S., Barry, G., Gao, D., O'Brien, P., Shepherd, L. E., Nielsen TO, & Gelmon, K. A. (2015). Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment, 149(2), 439–448. https://doi.org/10.1007/s10549-014-3259-1.
Dulak, A. M., Schumacher, S. E., van Lieshout, J., Imamura, Y., Fox, C., Shim, B., Ramos, A. H., Saksena, G., Baca, S. C., Baselga, J., Tabernero, J., Barretina, J., Enzinger, P. C., Corso, G., Roviello, F., Lin, L., Bandla, S., Luketich, J. D., Pennathur, A., Meyerson, M., Ogino, S., Shivdasani, R. A., Beer, D. G., Godfrey, T. E., Beroukhim, R., & Bass, A. J. (2012). Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Research, 72(17), 4383–4393.
Lee, J., Sohn, I., Do, I. G., Kim, K. M., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Sohn, T. S., Bae, J. M., Choi, M. G., Lim, D. H., Min, B. H., Lee, J. H., Rhee, P. L., Kim, J. J., Choi, D. I., Tan, I. B., Das, K., Tan, P., Jung, S. H., Kang, W. K., & Kim, S. (2014). Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One, 9, e90133.
Chen, K., Yang, D., Li, X., et al. (2015). Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proceedings of the National Academy of Sciences of the United States of America, 112, 1107e1112.
Busuttil, R. A., Zapparoli, G. V., Haupt, S., et al. (2014). Role of p53 in the progression of gastric cancer. Oncotarget, 5, 12016e12026. 4.
Endo, F., Nishizuka, S. S., Kume, K., Ishida, K., Katagiri, H., Ishida, K., Sato, K., Iwaya, T., Koeda, K., & Wakabayashi, G. (2014). A compensatory role of NF-kB to p53 in response to 5-FU-based chemotherapy for gastric cancer cell lines. PLoS One, 9, e90155.
Zha, Y., Gan, P., Liu, Q., & Yao, Q. (2016). TP53 codon 72 polymorphism predicts efficacy of paclitaxel plus capecitabine chemotherapy in advanced gastric cancer patients. Archives of Medical Research, 47(1), 13–18. https://doi.org/10.1016/j.arcmed.2015.12.001Epub 2015 Dec 13.
Das, K., Taguri, M., Imamura, H., Sugimoto, N., Nishikawa, K., Yoshida, K., Tan, P., & Tsuburaya, A. (2018). Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. Cancer Letters, 412, 208–215. https://doi.org/10.1016/j.canlet.2017.10.011.
Jardim, D. L., de Melo, G. D., Falchook, G. S., Janku, F., Zinner, R., Wheler, J. J., Subbiah, V., Piha-Paul, S. A., Fu, S., Murphy, M. B., Ajani, J., Tang, C., Hess, K., Hamilton, S. R., Roy-Chowdhuri, S., Kurzrock, R., Meric-Bernstam, F., & Hong, D. S. (2014). MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 5(7), 1837–1845.
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008). Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery, 7(6), 504–516.
Tuynman, J. B., Lagarde, S. M., Ten Kate, F. J., Richel, D. J., & van Lanschot, J. J. (2008). Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. British Journal of Cancer, 98(6), 1102–1108.
Lennerz, J. K., Kwak, E. L., Ackerman, A., Michael, M., Fox, S. B., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., Salgia, R., Bang, Y. J., Clark, J. W., Solomon, B. J., & Iafrate, A. J. (2011). MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology, 29(36), 4803–4810.
Stahl, M., Maderer, A., Lordick, F., Mihaljevic, A. L., Kanzler, S., Hoehler, T., Thuss-Patience, P., Mönig, S., Kunzmann, V., Schroll, S., Sandermann, A., Tannapfel, A., Meyer, H. J., Schuhmacher, C., Wilke, H., Moehler, M., & Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society. (2018). Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer, 93, 119–126. https://doi.org/10.1016/j.ejca.2018.01.079.
Kim, M. A., Lee, H. S., Lee, H. E., Jeon, Y. K., Yang, H. K., & Kim, W. H. (2008). EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology., 52(6), 738–746. https://doi.org/10.1111/j.1365-2559.2008.03021.x.
Cacina, C., Arikan, S., Duzkoylu, Y., Dogan, M. B., Okay, E., Turan, S., et al. (2015). Analyses of EGF A61G gene variation and serum EGF level on gastric cancer susceptibility and clinicopathological parameters. Anticancer Research, 35(5), 2709e13.
Park, D. J., Yoon, C., Thomas, N., Ku, G. Y., Janjigian, Y. Y., Kelsen, D. P., et al. (2014). Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Annals of Surgical Oncology, 21(4), 1130e7.
Takahashi, N., Furuta, K., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., et al. (2016). Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. Oncotarget, 7(4), 4925e38.
Lim, J. B., Kim, D. K., & Chung, H. W. (2014). Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker. Cancer Science, 105(10), 1327e33.
Jang, J. H., Shin, K. H., & Park, J. G. (2001). Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Research, 61, 3541–3543.
Murase, H., Inokuchi, M., Takagi, Y., et al. (2014). Prognostic significance of the co- overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. Molecular and Clinical Oncology, 2, 509–517.
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012). Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clinical Cancer Research, 18, 1855–1862.
Van Cutsem, E., Bang, Y. J., Mansoor, W., Petty, R. D., Chao, Y., Cunningham, D., Ferry, D. R., Smith, N. R., Frewer, P., Ratnayake, J., Stockman, P. K., Kilgour, E., & Landers, D. (2017). A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Annals of Oncology, 28(6), 1316–1324. https://doi.org/10.1093/annonc/mdx107.
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Konda, B., & Leichman, L. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology, 16, 309–316.
Yamada, Y., Boku, N., Nishina, T., Yamaguchi, K., Denda, T., Tsuji, A., Hamamoto, Y., Konishi, K., Tsuji, Y., Amagai, K., Ohkawa, S., Fujita, Y., Nishisaki, H., Kawai, H., Takashima, A., Mizusawa, J., Nakamura, K., & Ohtsu, A. (2013). Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Annals of Oncology, 24(10), 2560–2565. https://doi.org/10.1093/annonc/mdt238Epub 2013 Jul 24.
Deng, M., Tang, H. L., Lu, X. H., Liu, M. Y., Lu, X. M., Gu, Y. X., Liu, J. F., & He, Z. M. (2013). miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One, 8(8), e72662. https://doi.org/10.1371/journal.pone.0072662.
Ji, M., Xu, B., Jiang, J. T., Wu, J., Li, X. D., Zhao, W. Q., Zhang, H. Y., Zhou, W. J., & Wu, C. P. (2013). Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer. Onkologie, 36(6), 335–340. https://doi.org/10.1159/000351260.
Sato, F., & Meltzer, S. J. (2006). CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer, 106, 483–493.
Kang, C., Song, J. J., Lee, J., & Kim, M. Y. (2014). Epigenetics: an emerging player in gastric cancer. World journal of gastroenterology: WJG, 20, 6433–6447.
Hamilton, J. P., Sato, F., Jin, Z., Greenwald, B. D., Ito, T., Mori, Y., Paun, B. C., Kan, T., Cheng, Y., Wang, S., Yang, J., Abraham, J. M., & Meltzer, S. J. (2006). Reprimo methylation is a potential biomarker of Barrett’s-associated esophageal neoplastic progression. Clinical Cancer Research, 12, 6637–6642.
Eads, C. A., Lord, R. V., Wickramasinghe, K., Long, T. I., Kurumboor, S. K., Bernstein, L., Peters, J. H., DeMeester, S., DeMeester, T., Skinner, K. A., & Laird, P. W. (2001). Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Research, 61, 3410–3418.
Wang, J. S., Guo, M., Montgomery, E. A., Thompson, R. E., Cosby, H., Hicks, L., Wang, S., Herman, J. G., & Canto, M. I. (2009). DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus. The American Journal of Gastroenterology, 104, 2153–2160.
Oka, D., Yamashita, S., Tomioka, T., Nakanishi, Y., Kato, H., Kaminishi, M., & Ushijima, T. (2009). The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer, 115, 3412–3426.
Schneider, B. J., Shah, M. A., Klute, K., Ocean, A., Popa, E., Altorki, N., Lieberman, M., Schreiner, A., Yantiss, R., Christos, P. J., Palmer, R., You, D., Viale, A., Kermani, P., & Scandura, J. M. (2017). Phase I Study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response. Clinical Cancer Research, 23(11), 2673–2680. https://doi.org/10.1158/1078-0432.CCR-16-1896.
Marin, J. J., Al-Abdulla, R., Lozano, E., Briz, O., Bujanda, L., Banales, J. M., & Macias, R. I. (2016). Mechanisms of resistance to chemotherapy in gastric cancer. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 318–334 Review.
Khare, P. D., Shao-Xi, L., Kuroki, M., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y., & Kuroki, M. (2001). Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Research, 61(1), 370–375.
Shaw, D. M., Embleton, M. J., Westwater, C., Ryan, M. G., Myers, K. A., Kingsman, S. M., Carroll, M. W., & Stern, P. L. (2000). Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. Biochimica et Biophysica Acta, 1524(2–3), 238–246.
Biagioni, A., Chillà, A., Andreucci, E., Laurenzana, A., Margheri, F., Peppicelli, S., Del Rosso, M., & Fibbi, G. (2017). Type II CRISPR/Cas9 approach in the oncological therapy. Journal of Experimental & Clinical Cancer Research, 36(1), 80. https://doi.org/10.1186/s13046-017-0550-0Review.
Ohashi, M., Kanai, F., Ueno, H., Tanaka, T., Tateishi, K., Kawakami, T., Koike, Y., Ikenoue, T., Shiratori, Y., Hamada, H., & Omata, M. (1999). Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut, 44(3), 366–371.
Okino, T., Onda, M., Matsukura, N., Inada, K. I., Tatematsu, M., Suzuki, S., & Shimada, T. (2001). Sequential histopathological changes in vivo after suicide gene therapy of gastric cancer induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. Japanese Journal of Cancer Research, 92(6), 673–679.
Shimizu, T., Shimada, H., Ochiai, T., & Hamada, H. (2001). Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and herpes simplex virus thymidine kinase). Cancer Gene Therapy, 8, 512–521.
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017). Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nature Protocols, 12(4), 828–863. https://doi.org/10.1038/nprot.2017.016.
Financial support
Dr. Alessio Biagioni was supported by a postdoctoral fellowship of the Italian Foundation for Cancer Research (AIRC).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Biagioni, A., Skalamera, I., Peri, S. et al. Update on gastric cancer treatments and gene therapies. Cancer Metastasis Rev 38, 537–548 (2019). https://doi.org/10.1007/s10555-019-09803-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-019-09803-7